<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948829</url>
  </required_header>
  <id_info>
    <org_study_id>DEN-313</org_study_id>
    <secondary_id>U1111-1184-1893</secondary_id>
    <nct_id>NCT02948829</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children</brief_title>
  <official_title>An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the cellular immune responses following 2 doses given&#xD;
      3 months apart of tetravalent dengue vaccine candidate (TDV) in 4 to 16 years' healthy&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine tested in this study was TDV. This study assessed cellular immune responses and&#xD;
      safety up to 3 years post second TDV administration to healthy children aged 4 to 16 years&#xD;
      and in dengue endemic regions.&#xD;
&#xD;
      The study enrolled 200 participants. Participants received:&#xD;
&#xD;
      • TDV 0.5 mL subcutaneous (SC) injection into the upper arm at Day 1 (Month 0) and at Day 90&#xD;
      (Month 3).&#xD;
&#xD;
      This multi-center trial was conducted in Panama and Philippines. 198 participants received&#xD;
      the 2-dose schedule of TDV, and 2 participants received only the first dose of TDV (Day 1).&#xD;
      Participants made multiple visits to the clinic and were contacted at least every week for&#xD;
      the entire study duration post first injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Actual">December 14, 2020</completion_date>
  <primary_completion_date type="Actual">October 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination</measure>
    <time_frame>1 month post second vaccination (Day 120)</time_frame>
    <description>Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included non-structural protein (NS) for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination</measure>
    <time_frame>1 month post second vaccination (Day 120)</time_frame>
    <description>The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination and 6 Months Post Second Vaccination</measure>
    <time_frame>1 month post first vaccination (Day 30), and 6 months post second vaccination (Day 270)</time_frame>
    <description>Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1 [M0]) and &gt;=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination and 6 Months Post Second Vaccination</measure>
    <time_frame>1 month post first vaccination (Day 30) and 6 months post second vaccination (Day 270)</time_frame>
    <description>The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS protein for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Country</measure>
    <time_frame>1 month post first vaccination (Day 30), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
    <description>Percentage of participants with cellular immune response by country were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1 [M0]) and &gt;=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported as per enrollment by country (Panama and Philippines).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Dengue Baseline Seropositivity Status</measure>
    <time_frame>1 month post first vaccination (Day 30), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
    <description>Percentage of participants with cellular immune response by dengue Baseline seropositivity status were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1 [M0]) and &gt;=5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer &gt;=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer &lt;10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Country</measure>
    <time_frame>1 month post first vaccination (Day 30), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
    <description>The magnitude of cellular immune response by country was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS protein for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported as per enrollment by country (Panama and Philippines).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Dengue Baseline Seropositivity Status</measure>
    <time_frame>1 month post first vaccination (Day 30), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
    <description>The magnitude of cellular immune response by dengue Baseline seropositivity status was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer &gt;=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer &lt;10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Cellular Immune Responses to TDV in Participants &gt;10 Years of Age</measure>
    <time_frame>Day 14</time_frame>
    <description>Percentage of participants with cellular immune response in participants &gt;10 years of age were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1 [M0]) and &gt;=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. SFC/million PBMC for any peptide pool is reported in participants &gt;10 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants &gt;10 Years of Age</measure>
    <time_frame>Day 14</time_frame>
    <description>The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. SFC/million PBMC for any peptide pool is reported in participants &gt;10 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Proteins at 1 Month Post Second Vaccination Measured by Intracellular Cytokine Staining (ICS)</measure>
    <time_frame>1 month post second vaccination (Day 120)</time_frame>
    <description>The phenotype characterization of cellular immune response was assessed by the frequency of total cluster of differentiation 4 (CD4)+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses &gt;500 SFC/million cells and availability of sufficient cells. The peptide pools included NS for the DENV-2 serotype. Data are presented for the different expression profiles of interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) cytokines for each peptide pool. Data is reported based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Proteins at 1 Month Post Second Vaccination Assessed by Country</measure>
    <time_frame>1 month post second vaccination (Day 120)</time_frame>
    <description>The phenotype characterization of cellular immune response by country was assessed by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses &gt;500 SFC/million cells and availability of sufficient cells. The peptide pools included NS for the DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per country (Panama and Philippines) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Proteins at 1 Month Post Second Vaccination Assessed by Dengue Baseline Seropositivity Status</measure>
    <time_frame>1 month post second vaccination (Day 120)</time_frame>
    <description>The phenotype characterization of cellular immune response by dengue Baseline seropositivity status was assessed by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses &gt;500 SFC/million cells and availability of sufficient cells. Seropositive was defined as a reciprocal neutralizing titer (MNT50) &gt;=10 for one or more dengue serotypes. Seronegative was defined as titer value of &lt;10 for all 4 serotypes. The peptide pools included NS for the DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per Baseline seropositivity status (Seropositive and Seronegative) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination</measure>
    <time_frame>1 month post first vaccination (Day 30), 1 month pre second vaccination (Day 90), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
    <description>GMT of neutralizing antibodies was measured by microneutralization test (MTN). The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination</measure>
    <time_frame>1 month post first vaccination (Day 30), 1 month pre second vaccination (Day 90), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
    <description>Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination</measure>
    <time_frame>1 month post first vaccination (Day 30), 1 month pre second vaccination (Day 90), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
    <description>Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized in the following categories: tetravalent and at least trivalent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Unsolicited Adverse Events (AE)</measure>
    <time_frame>Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Medically Attended AEs (MAAEs)</measure>
    <time_frame>From first vaccination (Day 1) up to 6 months post second vaccination (Day 270) till Month 9 interim analysis data cut-off: 29 May 2018</time_frame>
    <description>MAAEs were defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>From first vaccination (Day 1) up to 6 months post second vaccination (Day 270) till Month 9 interim analysis data cut-off: 29 May 2018</time_frame>
    <description>A SAE was defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologically Confirmed Dengue</measure>
    <time_frame>From first vaccination (Day 1) up to 6 months post second vaccination (Day 270) till Month 9 interim analysis data cut-off: 29 May 2018</time_frame>
    <description>Participants with febrile illness defined as fever ≥38°C on any 2 of 3 consecutive days were evaluated for dengue. Virologically confirmed dengue was defined as febrile illness with a positive serotype-specific RT-PCR (i.e. positive dengue detection RT-PCR).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Tetravalent Dengue Vaccine (TDV) 0.5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TDV</intervention_name>
    <description>TDV SC injection.</description>
    <arm_group_label>Tetravalent Dengue Vaccine (TDV) 0.5 mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Is aged 4 to 16 years, inclusive (Latin America) or 4 to 8 years, inclusive (Asia).&#xD;
&#xD;
          2. Are in good health at the time of entry into the study as determined by medical&#xD;
             history, physical examination (including vital signs), and clinical judgment of the&#xD;
             investigator.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Febrile illness (body temperature ≥38°C) or moderate or severe acute illness or&#xD;
             infection at the time of enrolment.&#xD;
&#xD;
          2. History or any illness that, in the opinion of the investigator, might interfere with&#xD;
             the results of the study or pose an additional risk to the participant due to&#xD;
             participation in the study.&#xD;
&#xD;
          3. Receipt of any other vaccines within 14 days (for inactivated vaccines) or 28 days&#xD;
             (for live vaccines) prior to Day 1 (Month 0) or planning to receive any vaccines&#xD;
             within 28 days after Day 1 (Month 0).&#xD;
&#xD;
          4. Previous participation in any clinical study of a dengue candidate vaccine, or&#xD;
             previous receipt of any dengue vaccines (investigational or licensed).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CEVAXIN</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
    <country>Philippines</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <results_first_submitted>March 26, 2021</results_first_submitted>
  <results_first_submitted_qc>March 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2021</results_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT02948829/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT02948829/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 2 investigative sites in Panama and Philippines from 03 April 2017 to data cut-off date for Month 9 Interim Analysis: 29 May 2018.</recruitment_details>
      <pre_assignment_details>Healthy participants were enrolled in a single arm in this study to receive 2 doses of Tetravalent Dengue Vaccine (TDV) injection subcutaneously (SC).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
          <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing (at data cut-off date: 29 May 2018)</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with Study Procedures</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set included all enrolled participants who received at least 1 dose of TDV.</population>
      <group_list>
        <group group_id="B1">
          <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
          <description>TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.7" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Panama</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118.38" spread="14.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.54" spread="10.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI = weight (kg)/[height (m)^2]</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.15" spread="3.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Seropositivity Status</title>
          <description>Seropositive at Baseline was defined as a reciprocal neutralizing titer &gt;=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer &lt;10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Seropositive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Seronegative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination</title>
        <description>Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included non-structural protein (NS) for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
        <time_frame>1 month post second vaccination (Day 120)</time_frame>
        <population>Per-Protocol Set (PPS) included all participants from the Full Analysis Set (FAS) who have no major protocol violations. Overall number of participants analyzed are participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
            <description>TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination</title>
          <description>Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included non-structural protein (NS) for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
          <population>Per-Protocol Set (PPS) included all participants from the Full Analysis Set (FAS) who have no major protocol violations. Overall number of participants analyzed are participants with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1" lower_limit="80.1" upper_limit="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination</title>
        <description>The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
        <time_frame>1 month post second vaccination (Day 120)</time_frame>
        <population>PPS included all participants from the FAS who have no major protocol violations. Overall number of participants analyzed are participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells (SFC)/Million Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISPOT at 1 Month Post Second Vaccination</title>
          <description>The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
          <population>PPS included all participants from the FAS who have no major protocol violations. Overall number of participants analyzed are participants with data available for analysis.</population>
          <units>SFC/million PBMCs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1003.0" lower_limit="443.0" upper_limit="2126.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination and 6 Months Post Second Vaccination</title>
        <description>Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1 [M0]) and &gt;=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
        <time_frame>1 month post first vaccination (Day 30), and 6 months post second vaccination (Day 270)</time_frame>
        <population>PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cellular Immune Response to TDV at 1 Month Post First Vaccination and 6 Months Post Second Vaccination</title>
          <description>Percentage of participants with cellular immune response were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1 [M0]) and &gt;=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
          <population>PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0" lower_limit="79.8" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7" lower_limit="80.7" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination and 6 Months Post Second Vaccination</title>
        <description>The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS protein for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
        <time_frame>1 month post first vaccination (Day 30) and 6 months post second vaccination (Day 270)</time_frame>
        <population>PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination and 6 Months Post Second Vaccination</title>
          <description>The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS protein for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4.</description>
          <population>PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
          <units>SFC/million PBMCs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1181.0" lower_limit="585.0" upper_limit="2891.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="572.5" lower_limit="250.0" upper_limit="1382.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Country</title>
        <description>Percentage of participants with cellular immune response by country were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1 [M0]) and &gt;=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported as per enrollment by country (Panama and Philippines).</description>
        <time_frame>1 month post first vaccination (Day 30), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
        <population>PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL: Panama</title>
            <description>TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants in Panama.</description>
          </group>
          <group group_id="O2">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants in Philippines.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Country</title>
          <description>Percentage of participants with cellular immune response by country were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1 [M0]) and &gt;=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported as per enrollment by country (Panama and Philippines).</description>
          <population>PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2" lower_limit="78.7" upper_limit="94.4"/>
                    <measurement group_id="O2" value="84.2" lower_limit="75.3" upper_limit="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="73.7" upper_limit="91.4"/>
                    <measurement group_id="O2" value="87.8" lower_limit="79.6" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="81.7" upper_limit="96.2"/>
                    <measurement group_id="O2" value="83.7" lower_limit="74.8" upper_limit="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Dengue Baseline Seropositivity Status</title>
        <description>Percentage of participants with cellular immune response by dengue Baseline seropositivity status were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1 [M0]) and &gt;=5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer &gt;=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer &lt;10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative).</description>
        <time_frame>1 month post first vaccination (Day 30), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
        <population>PPS 'by Baseline seropositivity status' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seropositive</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants with seropositive status at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seronegative</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants with seronegative status at Baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cellular Immune Responses to TDV at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Dengue Baseline Seropositivity Status</title>
          <description>Percentage of participants with cellular immune response by dengue Baseline seropositivity status were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1 [M0]) and &gt;=5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer &gt;=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer &lt;10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative).</description>
          <population>PPS 'by Baseline seropositivity status' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" lower_limit="72.3" upper_limit="88.6"/>
                    <measurement group_id="O2" value="91.9" lower_limit="83.2" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0" lower_limit="73.1" upper_limit="89.0"/>
                    <measurement group_id="O2" value="91.8" lower_limit="83.0" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" lower_limit="71.1" upper_limit="87.5"/>
                    <measurement group_id="O2" value="95.8" lower_limit="88.3" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Country</title>
        <description>The magnitude of cellular immune response by country was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS protein for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported as per enrollment by country (Panama and Philippines).</description>
        <time_frame>1 month post first vaccination (Day 30), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
        <population>PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL: Panama</title>
            <description>TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants in Panama.</description>
          </group>
          <group group_id="O2">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL: Philippines</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants in Philippines.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Country</title>
          <description>The magnitude of cellular immune response by country was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Data (SFC/million PBMC) for participants with a cellular immune response to any peptide pool is reported. The peptide pool included NS protein for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported as per enrollment by country (Panama and Philippines).</description>
          <population>PPS 'by country' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>SFC/million PBMCs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1091.0" lower_limit="533.0" upper_limit="2988.0"/>
                    <measurement group_id="O2" value="1268.5" lower_limit="672.5" upper_limit="2797.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="919.0" lower_limit="360.0" upper_limit="1679.0"/>
                    <measurement group_id="O2" value="1086.0" lower_limit="513.0" upper_limit="2304.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439.0" lower_limit="215.5" upper_limit="1428.5"/>
                    <measurement group_id="O2" value="612.0" lower_limit="263.0" upper_limit="1264.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Dengue Baseline Seropositivity Status</title>
        <description>The magnitude of cellular immune response by dengue Baseline seropositivity status was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer &gt;=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer &lt;10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative).</description>
        <time_frame>1 month post first vaccination (Day 30), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
        <population>PPS 'by Baseline seropositivity status' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seropositive</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants with seropositive status at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL: Seronegative</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants with seronegative status at Baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination by Dengue Baseline Seropositivity Status</title>
          <description>The magnitude of cellular immune response by dengue Baseline seropositivity status was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Seropositive at Baseline was defined as a reciprocal neutralizing titer &gt;=10 for one or more dengue serotypes. Seronegative at Baseline was defined as having a reciprocal neutralizing titer &lt;10 for all dengue serotypes. The 4 dengue virus serotypes were dengue virus (DENV)-1, DENV-2, DENV-3 and DENV-4. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. Data is reported per Baseline seropositivity status of participants (Seropositive and Seronegative).</description>
          <population>PPS 'by Baseline seropositivity status' included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
          <units>SFC/million PBMCs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1735.0" lower_limit="736.0" upper_limit="3461.0"/>
                    <measurement group_id="O2" value="894.0" lower_limit="527.0" upper_limit="2011.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1216.0" lower_limit="584.0" upper_limit="2774.0"/>
                    <measurement group_id="O2" value="743.0" lower_limit="377.0" upper_limit="1546.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="719.0" lower_limit="287.0" upper_limit="1684.0"/>
                    <measurement group_id="O2" value="416.0" lower_limit="245.0" upper_limit="808.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Cellular Immune Responses to TDV in Participants &gt;10 Years of Age</title>
        <description>Percentage of participants with cellular immune response in participants &gt;10 years of age were reported. Cellular immune response was defined as an IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1 [M0]) and &gt;=5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. SFC/million PBMC for any peptide pool is reported in participants &gt;10 years of age.</description>
        <time_frame>Day 14</time_frame>
        <posting_date>09/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnitude of Cellular Immune Response Assessed by Number of SFC/Million PBMCs Measured by IFN-γ ELISPOT in Participants &gt;10 Years of Age</title>
        <description>The magnitude of cellular immune response was assessed by the number of SFC/million PBMCs for participants with a cellular immune response. Cellular immune response was defined as IFN-γ ELISPOT response that was &gt;3 times higher compared to Baseline (Day 1) and ≥ 5 spots per well. Cellular immune response to any peptide pool was reported. The peptide pool included NS for each of the dengue serotype: DENV-1, DENV-2, DENV-3 and DENV-4. SFC/million PBMC for any peptide pool is reported in participants &gt;10 years of age.</description>
        <time_frame>Day 14</time_frame>
        <posting_date>09/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Proteins at 1 Month Post Second Vaccination Measured by Intracellular Cytokine Staining (ICS)</title>
        <description>The phenotype characterization of cellular immune response was assessed by the frequency of total cluster of differentiation 4 (CD4)+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses &gt;500 SFC/million cells and availability of sufficient cells. The peptide pools included NS for the DENV-2 serotype. Data are presented for the different expression profiles of interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) cytokines for each peptide pool. Data is reported based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).</description>
        <time_frame>1 month post second vaccination (Day 120)</time_frame>
        <population>Intracellular Cytokine Staining (ICS) Subset population 'by T-cells' included subset selected among participants from PPS who have IFN-γ ELISPOT responses &gt;500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL: CD4+ T Cells</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants with CD4+ T cells at the time of analysis.</description>
          </group>
          <group group_id="O2">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL: CD8+ T Cells</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants with CD8+ T cells at the time of analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response to DENV-2 NS Proteins at 1 Month Post Second Vaccination Measured by Intracellular Cytokine Staining (ICS)</title>
          <description>The phenotype characterization of cellular immune response was assessed by the frequency of total cluster of differentiation 4 (CD4)+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses &gt;500 SFC/million cells and availability of sufficient cells. The peptide pools included NS for the DENV-2 serotype. Data are presented for the different expression profiles of interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) cytokines for each peptide pool. Data is reported based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).</description>
          <population>Intracellular Cytokine Staining (ICS) Subset population 'by T-cells' included subset selected among participants from PPS who have IFN-γ ELISPOT responses &gt;500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category.</population>
          <units>percentage of T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFNg+IL2+TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008340" lower_limit="0.003340" upper_limit="0.017000"/>
                    <measurement group_id="O2" value="0.001320" lower_limit="0.000000" upper_limit="0.004240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003410" lower_limit="0.001041" upper_limit="0.007190"/>
                    <measurement group_id="O2" value="0.010000" lower_limit="0.002650" upper_limit="0.018000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002100" lower_limit="0.000000" upper_limit="0.004710"/>
                    <measurement group_id="O2" value="0.007850" lower_limit="0.002230" upper_limit="0.027000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa-, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001050" lower_limit="0.000000" upper_limit="0.002420"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa-, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.001420"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.001800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa-, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.000935"/>
                    <measurement group_id="O2" value="0.000960" lower_limit="0.000000" upper_limit="0.002340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002110" lower_limit="0.000000" upper_limit="0.005070"/>
                    <measurement group_id="O2" value="0.007340" lower_limit="0.000000" upper_limit="0.029850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002000" lower_limit="0.000000" upper_limit="0.004160"/>
                    <measurement group_id="O2" value="0.116110" lower_limit="0.047000" upper_limit="0.317000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000860" lower_limit="0.000000" upper_limit="0.002820"/>
                    <measurement group_id="O2" value="0.096230" lower_limit="0.030050" upper_limit="0.207090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007160" lower_limit="0.002000" upper_limit="0.015040"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.004710"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003350" lower_limit="0.000000" upper_limit="0.009000"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.001250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa-, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002070" lower_limit="0.000000" upper_limit="0.005030"/>
                    <measurement group_id="O2" value="0.004080" lower_limit="0.000000" upper_limit="0.011000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa-, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000990" lower_limit="0.000000" upper_limit="0.002630"/>
                    <measurement group_id="O2" value="0.038000" lower_limit="0.013270" upper_limit="0.094810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa-, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.002480"/>
                    <measurement group_id="O2" value="0.018850" lower_limit="0.007000" upper_limit="0.060560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa-, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009000" lower_limit="0.000000" upper_limit="0.014000"/>
                    <measurement group_id="O2" value="0.002000" lower_limit="0.000000" upper_limit="0.014000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa-, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001000" lower_limit="0.000000" upper_limit="0.010000"/>
                    <measurement group_id="O2" value="0.001000" lower_limit="0.000000" upper_limit="0.017000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa-, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.013000"/>
                    <measurement group_id="O2" value="0.001000" lower_limit="0.000000" upper_limit="0.015000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2-TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002000" lower_limit="0.000000" upper_limit="0.028000"/>
                    <measurement group_id="O2" value="0.004000" lower_limit="0.000000" upper_limit="0.020000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2-TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.030000"/>
                    <measurement group_id="O2" value="0.012000" lower_limit="0.000000" upper_limit="0.028000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2-TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020000" lower_limit="0.000000" upper_limit="0.050000"/>
                    <measurement group_id="O2" value="0.012000" lower_limit="0.000000" upper_limit="0.030000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Proteins at 1 Month Post Second Vaccination Assessed by Country</title>
        <description>The phenotype characterization of cellular immune response by country was assessed by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses &gt;500 SFC/million cells and availability of sufficient cells. The peptide pools included NS for the DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per country (Panama and Philippines) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).</description>
        <time_frame>1 month post second vaccination (Day 120)</time_frame>
        <population>ICS Subset population 'by country based on T-cells' included subset selected among participants from PPS who have IFN-γ ELISPOT responses &gt;500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category.</population>
        <group_list>
          <group group_id="O1">
            <title>TDV 0.5 mL: Panama: CD4+ T Cells</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants in Panama with CD4+ T cells at the time of analysis.</description>
          </group>
          <group group_id="O2">
            <title>TDV 0.5 mL: Philippines: CD4+ T Cells</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants in Panama with CD4+ T cells at the time of analysis.</description>
          </group>
          <group group_id="O3">
            <title>TDV 0.5 mL: Panama: CD8+ T Cells</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants in Panama with CD8+ T cells at the time of analysis.</description>
          </group>
          <group group_id="O4">
            <title>TDV 0.5 ml: Philippines: CD8+ T Cells</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants in Panama with CD8+ T cells at the time of analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Proteins at 1 Month Post Second Vaccination Assessed by Country</title>
          <description>The phenotype characterization of cellular immune response by country was assessed by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses &gt;500 SFC/million cells and availability of sufficient cells. The peptide pools included NS for the DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per country (Panama and Philippines) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).</description>
          <population>ICS Subset population 'by country based on T-cells' included subset selected among participants from PPS who have IFN-γ ELISPOT responses &gt;500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category.</population>
          <units>percentage of T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFNg+IL2+TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005531" lower_limit="0.003340" upper_limit="0.012780"/>
                    <measurement group_id="O2" value="0.009230" lower_limit="0.003860" upper_limit="0.018610"/>
                    <measurement group_id="O3" value="0.001590" lower_limit="0.000000" upper_limit="0.006910"/>
                    <measurement group_id="O4" value="0.001100" lower_limit="0.000000" upper_limit="0.002580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002690" lower_limit="0.001041" upper_limit="0.007190"/>
                    <measurement group_id="O2" value="0.003495" lower_limit="0.001420" upper_limit="0.006660"/>
                    <measurement group_id="O3" value="0.010000" lower_limit="0.002850" upper_limit="0.016000"/>
                    <measurement group_id="O4" value="0.010000" lower_limit="0.002650" upper_limit="0.019000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000661" lower_limit="0.000000" upper_limit="0.002990"/>
                    <measurement group_id="O2" value="0.002598" lower_limit="0.000000" upper_limit="0.005470"/>
                    <measurement group_id="O3" value="0.013000" lower_limit="0.004830" upper_limit="0.021000"/>
                    <measurement group_id="O4" value="0.006905" lower_limit="0.001180" upper_limit="0.028000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa-, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000900" lower_limit="0.000000" upper_limit="0.002580"/>
                    <measurement group_id="O2" value="0.001135" lower_limit="0.000000" upper_limit="0.002180"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa-, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.001670"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.000000" upper_limit="0.001440"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.001920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa-, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.001190"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.000000" upper_limit="0.001650"/>
                    <measurement group_id="O4" value="0.001175" lower_limit="0.000000" upper_limit="0.003450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002396" lower_limit="0.000260" upper_limit="0.005000"/>
                    <measurement group_id="O2" value="0.002045" lower_limit="0.000000" upper_limit="0.005070"/>
                    <measurement group_id="O3" value="0.011000" lower_limit="0.001100" upper_limit="0.066340"/>
                    <measurement group_id="O4" value="0.005500" lower_limit="0.000000" upper_limit="0.019000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002456" lower_limit="0.000250" upper_limit="0.005980"/>
                    <measurement group_id="O2" value="0.001800" lower_limit="0.000000" upper_limit="0.003200"/>
                    <measurement group_id="O3" value="0.092920" lower_limit="0.038250" upper_limit="0.160000"/>
                    <measurement group_id="O4" value="0.153500" lower_limit="0.048520" upper_limit="0.353170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001590" lower_limit="0.000000" upper_limit="0.002636"/>
                    <measurement group_id="O2" value="0.000702" lower_limit="0.000000" upper_limit="0.002960"/>
                    <measurement group_id="O3" value="0.094740" lower_limit="0.030050" upper_limit="0.205000"/>
                    <measurement group_id="O4" value="0.096615" lower_limit="0.031580" upper_limit="0.220000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005710" lower_limit="0.000000" upper_limit="0.010000"/>
                    <measurement group_id="O2" value="0.008335" lower_limit="0.002900" upper_limit="0.017000"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.005520"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.004000"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.00000" upper_limit="0.00000"/>
                    <measurement group_id="O4" value="0.00000" lower_limit="0.00000" upper_limit="0.00000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003580" lower_limit="0.000000" upper_limit="0.008000"/>
                    <measurement group_id="O2" value="0.003275" lower_limit="0.000000" upper_limit="0.010660"/>
                    <measurement group_id="O3" value="0.00000" lower_limit="0.00000" upper_limit="0.00000"/>
                    <measurement group_id="O4" value="0.00000" lower_limit="0.00000" upper_limit="0.001250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa-, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002490" lower_limit="0.000000" upper_limit="0.005560"/>
                    <measurement group_id="O2" value="0.001520" lower_limit="0.000000" upper_limit="0.004380"/>
                    <measurement group_id="O3" value="0.006000" lower_limit="0.001770" upper_limit="0.019000"/>
                    <measurement group_id="O4" value="0.003750" lower_limit="0.000000" upper_limit="0.007240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa-, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001620" lower_limit="0.000000" upper_limit="0.002630"/>
                    <measurement group_id="O2" value="0.000365" lower_limit="0.000000" upper_limit="0.002000"/>
                    <measurement group_id="O3" value="0.033420" lower_limit="0.009000" upper_limit="0.081860"/>
                    <measurement group_id="O4" value="0.039000" lower_limit="0.015000" upper_limit="0.104850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa-, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.002000"/>
                    <measurement group_id="O2" value="0.000205" lower_limit="0.000000" upper_limit="0.002830"/>
                    <measurement group_id="O3" value="0.022820" lower_limit="0.012340" upper_limit="0.058000"/>
                    <measurement group_id="O4" value="0.018425" lower_limit="0.004130" upper_limit="0.060560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa-, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010000" lower_limit="0.000000" upper_limit="0.015000"/>
                    <measurement group_id="O2" value="0.007000" lower_limit="0.000000" upper_limit="0.012000"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.000000" upper_limit="0.008000"/>
                    <measurement group_id="O4" value="0.002000" lower_limit="0.000000" upper_limit="0.017000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa-, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.005000"/>
                    <measurement group_id="O2" value="0.001500" lower_limit="0.000000" upper_limit="0.011000"/>
                    <measurement group_id="O3" value="0.005000" lower_limit="0.000000" upper_limit="0.017000"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.012000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa-, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001000" lower_limit="0.000000" upper_limit="0.013000"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.013000"/>
                    <measurement group_id="O3" value="0.005000" lower_limit="0.000000" upper_limit="0.015000"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.014000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2-TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001000" lower_limit="0.000000" upper_limit="0.020000"/>
                    <measurement group_id="O2" value="0.002000" lower_limit="0.000000" upper_limit="0.030000"/>
                    <measurement group_id="O3" value="0.004000" lower_limit="0.000000" upper_limit="0.017000"/>
                    <measurement group_id="O4" value="0.003000" lower_limit="0.000000" upper_limit="0.020000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2-TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.030000"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.028000"/>
                    <measurement group_id="O3" value="0.010000" lower_limit="0.000000" upper_limit="0.020000"/>
                    <measurement group_id="O4" value="0.016500" lower_limit="0.000000" upper_limit="0.033000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2-TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020000" lower_limit="0.000000" upper_limit="0.050000"/>
                    <measurement group_id="O2" value="0.015000" lower_limit="0.000000" upper_limit="0.049000"/>
                    <measurement group_id="O3" value="0.013000" lower_limit="0.000000" upper_limit="0.027340"/>
                    <measurement group_id="O4" value="0.011000" lower_limit="0.000000" upper_limit="0.031000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Proteins at 1 Month Post Second Vaccination Assessed by Dengue Baseline Seropositivity Status</title>
        <description>The phenotype characterization of cellular immune response by dengue Baseline seropositivity status was assessed by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses &gt;500 SFC/million cells and availability of sufficient cells. Seropositive was defined as a reciprocal neutralizing titer (MNT50) &gt;=10 for one or more dengue serotypes. Seronegative was defined as titer value of &lt;10 for all 4 serotypes. The peptide pools included NS for the DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per Baseline seropositivity status (Seropositive and Seronegative) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).</description>
        <time_frame>1 month post second vaccination (Day 120)</time_frame>
        <population>ICS Subset population 'by Baseline seropositivity status based on T-cells' included subset selected among participants from PPS who have IFN-γ ELISPOT responses &gt;500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category.</population>
        <group_list>
          <group group_id="O1">
            <title>TDV 0.5 mL: Seropositive: CD4+ T-Cells</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants with seropositive status at Baseline having CD4+ at the time of analysis.</description>
          </group>
          <group group_id="O2">
            <title>TDV 0.5 mL: Seronegative: CD4+ T-Cells</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants with seronegative status at Baseline having CD4+ at the time of analysis.</description>
          </group>
          <group group_id="O3">
            <title>TDV 0.5 mL: Seropositive: CD8+ T Cells</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants with seropositive status at Baseline having CD4+ at the time of analysis.</description>
          </group>
          <group group_id="O4">
            <title>TDV 0.5 mL: Seronegative: CD8+ T-Cells</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3) was received by participants with seronegative status at Baseline having CD4+ at the time of analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Phenotype Characterization of Cellular Immune Response Assessed by Percentage of Total T Cells of Cellular Response DENV-2 NS Proteins at 1 Month Post Second Vaccination Assessed by Dengue Baseline Seropositivity Status</title>
          <description>The phenotype characterization of cellular immune response by dengue Baseline seropositivity status was assessed by the frequency of total CD4+ and CD8+ T cells and was performed in a subset of participants with IFN- γ ELISPOT responses &gt;500 SFC/million cells and availability of sufficient cells. Seropositive was defined as a reciprocal neutralizing titer (MNT50) &gt;=10 for one or more dengue serotypes. Seronegative was defined as titer value of &lt;10 for all 4 serotypes. The peptide pools included NS for the DENV-2 serotype. Data are presented for the different expression profiles of IFN-γ, IL-2 and TNF-α cytokines for each peptide pool. Data is reported per Baseline seropositivity status (Seropositive and Seronegative) based on the type of T cells present in participants at the time of analysis (CD4+ T cells and CD8+ T cells).</description>
          <population>ICS Subset population 'by Baseline seropositivity status based on T-cells' included subset selected among participants from PPS who have IFN-γ ELISPOT responses &gt;500 SFC/million PBMCs and availability of sufficient cells. Number analyzed is the number of participants with data available for analysis for specific category.</population>
          <units>percentage of T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFNg+IL2+TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011000" lower_limit="0.003860" upper_limit="0.017000"/>
                    <measurement group_id="O2" value="0.005531" lower_limit="0.003340" upper_limit="0.016010"/>
                    <measurement group_id="O3" value="0.001400" lower_limit="0.000000" upper_limit="0.004030"/>
                    <measurement group_id="O4" value="0.001320" lower_limit="0.000000" upper_limit="0.004240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003480" lower_limit="0.000000" upper_limit="0.008830"/>
                    <measurement group_id="O2" value="0.003300" lower_limit="0.001670" upper_limit="0.005510"/>
                    <measurement group_id="O3" value="0.010000" lower_limit="0.002650" upper_limit="0.028000"/>
                    <measurement group_id="O4" value="0.010000" lower_limit="0.002740" upper_limit="0.015000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002705" lower_limit="0.000000" upper_limit="0.005470"/>
                    <measurement group_id="O2" value="0.001460" lower_limit="0.000000" upper_limit="0.003000"/>
                    <measurement group_id="O3" value="0.012000" lower_limit="0.002670" upper_limit="0.035000"/>
                    <measurement group_id="O4" value="0.006000" lower_limit="0.002230" upper_limit="0.013000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa-, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000975" lower_limit="0.000000" upper_limit="0.002670"/>
                    <measurement group_id="O2" value="0.001220" lower_limit="0.000000" upper_limit="0.001840"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa-, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.001580"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.001150"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.000000" upper_limit="0.001920"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.001460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2+TNFa-, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.000908"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.000953"/>
                    <measurement group_id="O3" value="0.001540" lower_limit="0.000000" upper_limit="0.003450"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.001650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002885" lower_limit="0.000760" upper_limit="0.005320"/>
                    <measurement group_id="O2" value="0.002070" lower_limit="0.000000" upper_limit="0.003680"/>
                    <measurement group_id="O3" value="0.007155" lower_limit="0.000000" upper_limit="0.036000"/>
                    <measurement group_id="O4" value="0.007850" lower_limit="0.000000" upper_limit="0.028000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002915" lower_limit="0.001090" upper_limit="0.004370"/>
                    <measurement group_id="O2" value="0.000450" lower_limit="0.000000" upper_limit="0.002670"/>
                    <measurement group_id="O3" value="0.144565" lower_limit="0.039110" upper_limit="0.447000"/>
                    <measurement group_id="O4" value="0.093000" lower_limit="0.053410" upper_limit="0.163270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000702" lower_limit="0.000000" upper_limit="0.003690"/>
                    <measurement group_id="O2" value="0.001570" lower_limit="0.000000" upper_limit="0.002150"/>
                    <measurement group_id="O3" value="0.102525" lower_limit="0.039880" upper_limit="0.291210"/>
                    <measurement group_id="O4" value="0.078900" lower_limit="0.025190" upper_limit="0.134400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004735" lower_limit="0.000280" upper_limit="0.013000"/>
                    <measurement group_id="O2" value="0.011430" lower_limit="0.003910" upper_limit="0.017000"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000530" lower_limit="0.000000" upper_limit="0.005520"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.003730"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.001140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003100" lower_limit="0.000000" upper_limit="0.007000"/>
                    <measurement group_id="O2" value="0.006490" lower_limit="0.000000" upper_limit="0.010660"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.000000" upper_limit="0.001420"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa-, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001520" lower_limit="0.000000" upper_limit="0.004710"/>
                    <measurement group_id="O2" value="0.002490" lower_limit="0.000000" upper_limit="0.005030"/>
                    <measurement group_id="O3" value="0.004280" lower_limit="0.001060" upper_limit="0.009270"/>
                    <measurement group_id="O4" value="0.004080" lower_limit="0.000000" upper_limit="0.016790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa-, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001235" lower_limit="0.000000" upper_limit="0.002480"/>
                    <measurement group_id="O2" value="0.000190" lower_limit="0.000000" upper_limit="0.002720"/>
                    <measurement group_id="O3" value="0.046825" lower_limit="0.015000" upper_limit="0.111210"/>
                    <measurement group_id="O4" value="0.024000" lower_limit="0.000000" upper_limit="0.056110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg+IL2-TNFa-, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000020" lower_limit="0.000000" upper_limit="0.002480"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.002260"/>
                    <measurement group_id="O3" value="0.034610" lower_limit="0.011000" upper_limit="0.101210"/>
                    <measurement group_id="O4" value="0.016280" lower_limit="0.006480" upper_limit="0.030630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa-, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009500" lower_limit="0.000000" upper_limit="0.011000"/>
                    <measurement group_id="O2" value="0.006000" lower_limit="0.000000" upper_limit="0.015000"/>
                    <measurement group_id="O3" value="0.001500" lower_limit="0.000000" upper_limit="0.017000"/>
                    <measurement group_id="O4" value="0.002000" lower_limit="0.000000" upper_limit="0.014000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa-, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.007000"/>
                    <measurement group_id="O2" value="0.002000" lower_limit="0.000000" upper_limit="0.011000"/>
                    <measurement group_id="O3" value="0.000500" lower_limit="0.000000" upper_limit="0.019000"/>
                    <measurement group_id="O4" value="0.003000" lower_limit="0.000000" upper_limit="0.012000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2+TNFa-, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" lower_limit="0.000000" upper_limit="0.013000"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.013000"/>
                    <measurement group_id="O3" value="0.000000" lower_limit="0.000000" upper_limit="0.011000"/>
                    <measurement group_id="O4" value="0.006000" lower_limit="0.000000" upper_limit="0.020000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2-TNFa+, DENV-2, NS1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007000" lower_limit="0.000000" upper_limit="0.040000"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.019000"/>
                    <measurement group_id="O3" value="0.004500" lower_limit="0.000000" upper_limit="0.028000"/>
                    <measurement group_id="O4" value="0.000000" lower_limit="0.000000" upper_limit="0.014000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2-TNFa+, DENV-2, NS3-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008000" lower_limit="0.000000" upper_limit="0.030000"/>
                    <measurement group_id="O2" value="0.000000" lower_limit="0.000000" upper_limit="0.028000"/>
                    <measurement group_id="O3" value="0.018000" lower_limit="0.000000" upper_limit="0.034000"/>
                    <measurement group_id="O4" value="0.009000" lower_limit="0.000000" upper_limit="0.019000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg-IL2-TNFa+, DENV-2, NS5-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020000" lower_limit="0.000000" upper_limit="0.050000"/>
                    <measurement group_id="O2" value="0.010000" lower_limit="0.000000" upper_limit="0.040000"/>
                    <measurement group_id="O3" value="0.016500" lower_limit="0.000000" upper_limit="0.040000"/>
                    <measurement group_id="O4" value="0.008000" lower_limit="0.000000" upper_limit="0.023050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination</title>
        <description>GMT of neutralizing antibodies was measured by microneutralization test (MTN). The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.</description>
        <time_frame>1 month post first vaccination (Day 30), 1 month pre second vaccination (Day 90), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
        <population>PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination</title>
          <description>GMT of neutralizing antibodies was measured by microneutralization test (MTN). The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.</description>
          <population>PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DENV-1, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402.3" lower_limit="287.5" upper_limit="562.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-2, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5482.2" lower_limit="4626.4" upper_limit="6496.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-3, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436.1" lower_limit="326.9" upper_limit="581.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-4, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.9" lower_limit="182.6" upper_limit="353.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-1, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.7" lower_limit="193.9" upper_limit="380.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-2, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2736.3" lower_limit="2295.1" upper_limit="3262.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-3, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.7" lower_limit="162.0" upper_limit="295.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-4, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.4" lower_limit="129.6" upper_limit="242.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-1, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550.6" lower_limit="408.0" upper_limit="743.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-2, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2808.2" lower_limit="2395.0" upper_limit="3292.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-3, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404.2" lower_limit="312.6" upper_limit="522.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-4, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427.1" lower_limit="335.4" upper_limit="543.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-1, Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343.3" lower_limit="249.8" upper_limit="471.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-2, Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1729.9" lower_limit="1435.7" upper_limit="2084.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-3, Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.8" lower_limit="153.5" upper_limit="270.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-4, Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.6" lower_limit="141.6" upper_limit="246.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination</title>
        <description>Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.</description>
        <time_frame>1 month post first vaccination (Day 30), 1 month pre second vaccination (Day 90), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
        <population>PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Seropositive for Each of the 4 Dengue Serotypes at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination</title>
          <description>Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.</description>
          <population>PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DENV-1, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="93.1" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-2, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-3, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-4, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="88.3" upper_limit="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-1, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8" lower_limit="85.8" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-2, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-3, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4" lower_limit="90.1" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-4, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.8" lower_limit="87.0" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-1, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-2, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-3, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-4, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-1, Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="93.1" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-2, Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-3, Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="94.6" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-4, Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="93.1" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination</title>
        <description>Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized in the following categories: tetravalent and at least trivalent.</description>
        <time_frame>1 month post first vaccination (Day 30), 1 month pre second vaccination (Day 90), 1 and 6 months post second vaccination (Days 120 and 270)</time_frame>
        <population>PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Seropositive for Multiple Dengue Serotypes at 1 Month Post First Vaccination, and 1 and 6 Months Post Second Vaccination</title>
          <description>Seropositive was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositive for multiple dengue serotypes were summarized in the following categories: tetravalent and at least trivalent.</description>
          <population>PPS included all participants from the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tetravalent, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8" lower_limit="85.7" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least Trivalent, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="95.3" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetravalent, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="77.6" upper_limit="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least Trivalent, Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" lower_limit="91.4" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetravalent, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least Trivalent, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetravalent, Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="88.4" upper_limit="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least Trivalent, Day 270</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="95.4" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Unsolicited Adverse Events (AE)</title>
        <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.</description>
        <time_frame>Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]</time_frame>
        <population>Safety Set included all enrolled participants who received at least 1 dose of TDV. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Unsolicited Adverse Events (AE)</title>
          <description>An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.</description>
          <population>Safety Set included all enrolled participants who received at least 1 dose of TDV. Number analyzed is the number of participants with data available for analysis at the given timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After First Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Medically Attended AEs (MAAEs)</title>
        <description>MAAEs were defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.</description>
        <time_frame>From first vaccination (Day 1) up to 6 months post second vaccination (Day 270) till Month 9 interim analysis data cut-off: 29 May 2018</time_frame>
        <population>Safety Set included all enrolled participants who received at least 1 dose of TDV.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Medically Attended AEs (MAAEs)</title>
          <description>MAAEs were defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.</description>
          <population>Safety Set included all enrolled participants who received at least 1 dose of TDV.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serious Adverse Events (SAEs)</title>
        <description>A SAE was defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
        <time_frame>From first vaccination (Day 1) up to 6 months post second vaccination (Day 270) till Month 9 interim analysis data cut-off: 29 May 2018</time_frame>
        <population>Safety Set included all enrolled participants who received at least 1 dose of TDV.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events (SAEs)</title>
          <description>A SAE was defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
          <population>Safety Set included all enrolled participants who received at least 1 dose of TDV.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologically Confirmed Dengue</title>
        <description>Participants with febrile illness defined as fever ≥38°C on any 2 of 3 consecutive days were evaluated for dengue. Virologically confirmed dengue was defined as febrile illness with a positive serotype-specific RT-PCR (i.e. positive dengue detection RT-PCR).</description>
        <time_frame>From first vaccination (Day 1) up to 6 months post second vaccination (Day 270) till Month 9 interim analysis data cut-off: 29 May 2018</time_frame>
        <population>Safety Set included all enrolled participants who received at least 1 dose of TDV.</population>
        <group_list>
          <group group_id="O1">
            <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
            <description>TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologically Confirmed Dengue</title>
          <description>Participants with febrile illness defined as fever ≥38°C on any 2 of 3 consecutive days were evaluated for dengue. Virologically confirmed dengue was defined as febrile illness with a positive serotype-specific RT-PCR (i.e. positive dengue detection RT-PCR).</description>
          <population>Safety Set included all enrolled participants who received at least 1 dose of TDV.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality and Serious adverse events: From first vaccination (Day 1) up to 6 months post second vaccination (Day 270) till Month 9 interim analysis data cut-off: 29 May 2018; Non-serious adverse events: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tetravalent Dengue Vaccine (TDV) 0.5 mL</title>
          <description>TDV 0.5 mL, SC injection, on Day 1 (Month 0) and Day 90 (Month 3).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA: 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA: 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Systemic viral infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

